×
3 304
Fashion Jobs
TK MAXX
Tkmaxx Full-Time Loss Prevention Officer-Waltham Abbey
Permanent · London
TK MAXX
tk Maxx - Loss Prevention Officer - Full Time - Loughton
Permanent · London
TK MAXX
Tkmaxx Full-Time Loss Prevention Officer - Hackney
Permanent · London
DR. MARTENS
Financial Analyst, Apac
Permanent · TSIM SHA TSUI
SELFRIDGES
Finance Analyst – Digital & Customer
Permanent · LONDON
SELFRIDGES
Digital Personal Shopping Consultant (Thai Speaker)
Permanent · LONDON
SELFRIDGES
Finance Manager – Domains
Permanent · LONDON
HARVEY NICHOLS
Brand Consultant - Chloe
Permanent · LONDON
SPORTS DIRECT
Loss Prevention Supervisor
Permanent · LONDON
SPORTS DIRECT
Loss Prevention Supervisor
Permanent · ORPINGTON
HUGO BOSS UK LTD.
Sales Executive Boss Menswear
Permanent ·
TK MAXX
Loss Prevention Officer - Permanent - tk Maxx - Milton Keynes
Permanent · Milton Keynes
HOLLISTER CO. STORES
Hollister CO. - Graduate Manager in Training, Stratford (Westfield)
Permanent · London
UNDER ARMOUR
Stock Lead, ft (40 Hours)
Permanent · LONDON
SELFRIDGES
Finance Analyst- Domain
Permanent · LONDON
SELFRIDGES
Tech Business Analyst - Customer & Omni
Permanent · LONDON
HARVEY NICHOLS
Brand Consultant - Paul Smith
Permanent · LONDON
BURBERRY
Senior IT Operations Manager
Permanent · LONDON
BURBERRY
IT Project Manager
Permanent · LONDON
REISS
Retail Operations Coordinator-Part Time
Permanent · LONDON
REISS
Retail Operations Coordinator
Permanent · LONDON
HEAD OFFICE
Buyer, Waitrose & Partners (Level 7)
Permanent · BRACKNELL
Ads
By
Reuters API
Published
Jan 23, 2018
Share
Download
Download the article
Print
Click here to print
Text size
aA+ aA-

J&J reports quarterly loss on $13.6 billion tax charge

By
Reuters API
Published
Jan 23, 2018

Johnson & Johnson reported a quarterly loss due to a $13.6 billion (9.75 billion pounds) charge related to the new U.S. tax law, but beat adjusted quarterly profit estimate on strong demand for new cancer drugs and gains from its Actelion acquisition.


Photo: Neutrogena


A number of U.S. companies with sizable international operations are booking huge charges related to the new tax law, which encourages companies to repatriate their offshore earnings.

International operations accounted for nearly a half of J&J's total fourth-quarter sales of $20.20 billion, which was up 11.5 percent from a year earlier.

Higher sales of cancer drugs Darzalex and Imbruvica, and psoriasis drug Tremfya helped drive a 17.6 percent rise in pharmaceuticals sales to $9.68 billion, the company said.

High-margin treatments from Actelion, which was acquired by J&J for $30 billion in 2016, accounted for about a quarter of the pharmaceutical unit's sales growth.

Sales at J&J's consumer products unit, which makes Band-Aids, Neutrogena beauty products and Tylenol, rose 3.1 percent to $3.5 billion.

The net loss was $10.71 billion, or $3.99 per share, for the latest quarter, compared with a profit of $3.81 billion, or $1.38 per share, a year earlier.

Excluding items, J&J earned $1.74 per share, slightly above the analysts' average estimate of $1.72 per share, according to Thomson Reuters I/B/E/S.

J&J forecast an adjusted profit of $8 to $8.20 per share on revenue of $80.6 billion to $81.4 billion for 2018.
Analysts on average were expecting a profit of $7.87 per share and revenue of $80.7 billion.

Shares of the company were up marginally in premarket trading.

 

© Thomson Reuters 2023 All rights reserved.